Long-term effects of antitumor treatment of acute lymphoblastic leukemia
https://doi.org/10.33667/2078-5631-2025-26-41-48
Abstract
Introduction. In recent decades, the five-year survival rate of children with acute lymphoblastic leukemia (ALL) in Russia has risen to over 90 %. At the same time, this group of patients remains at serious risk of developing long-term effects of therapy, including secondary malignant neoplasms, cardiotoxicity, neurocognitive disorders, as well as pathologies of the musculoskeletal apparatus and endocrine system. The main risk factors for late effects are: intensity and combination of chemotherapy/radiation therapy, age at the time of treatment, genetic predisposition (gene polymorphisms, variations in DNA repair genes), as well as the presence of concomitant diseases (congenital heart disease, obesity).
Objective. To systematize and summarize current data on the spectrum and frequency of late adverse effects in patients treated for ALL during childhood.
Materials and methods. Data were structured review and analyzed in electronic medical databases such as PubMed, eLibrary from 1990 to 2024.
Conclusions. These reviews emphasize the high prevalence of a variety of late adverse effects in children cured of ALL and the need for their systematic monitoring.
About the Authors
A. R. Sittigullina
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Sittigullina Adilya R. resident at the Research Institute of Pediatric Oncology and Hematology named after academician of the Russian Academy of Medical Sciences L. A. Durnov
Moscow
V. Kh. Kharbediya
Federal Children’s Rehabilitation Center «Korablik» – structural division of the Russian Children’s Clinical Hospital – branch of the N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Kharbediya Vahtang Kh. pediatric oncologist, head of Pediatric Oncology Rehabilitation Dept
Podolsk
T. S. Belysheva
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Belysheva Tatiana S., DM Sci (habil.), leading researcher at Outpatient Dept of the Research Institute of Pediatric Oncology and Hematology named after academician of the Russian Academy of Medical Sciences L. A. Durnov
Moscow
References
1. Aleskerova G. A., Shervashidze M. A., Popa A. V., Valiev T. T., Kurdjukov B. V., Batmanova N. A., Mentkevich G. L. Treatment Results of All IC-BFM 2002 Protocol in Children with Acute Lymphoblastic Leukemia. Onkopediatria. 2016; 3 (4): 302–308. (In Russ.). DOI: 10.15690/onco.v3i4.1635
2. Saleh T. A., Al-Rubaye A.S., Noori A. S., Ibrahim I. K. Assessment of anthracycline-induced longterm cardiotoxicity in patients with hematological malignancies. Iraqi Journal of Hematology. 2019; 8 (2): 63–68. DOI: 10.4103/ijh.ijh_4_19
3. Vinogradova Yu.E., Lutsenko I. N., Kaplanskaia I. B., Vorob’ev I.A., Samoĭlova R. S., Gorgidze L. A., Ryzhikova N. A., Valiev T. T., Giliazitdinova E. A., Dzhulakian U. L., Egorova E. K., Zvonkov E. E., Krasil’nikova B.B., Magomedova A. U., Margolin O. V., Mar’in D.S., Kremenetskaia A. M., Kravchenko S. K., Vorob’ev A. I. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskii arkhiv. 2008; 80 (7): 33–37. (In Russ.).
4. Valiev T. T., Morozova O. V., Kovrigina A. M., Makhonova L. A., Sholokhova E. N., Serebryakova I. N., Popa A. V., Tupitsyn N. N., Mentkevich G. L. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Russian journal of hematology and transfusiology. 2012; 57 (1): 3–9. (In Russ.).
5. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010; 170 (14): 1247–1255. DOI: 10.1001/archinternmed.2010.233
6. Zaeva G. E., Valiev T. T., Gavrilenko T. F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Journal of Modern Oncology. 2015; 18 (1): 55–60. (In Russ.).
7. Lipshultz SE, Lipsitz SR, Sallan SE. et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23 (12): 2629–2636. DOI: 10.1200/JCO.2005.11.015
8. Gurieva O. D., Savelyeva M. I., Valiev T. T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Russian Journal of Pediatric Hematology and Oncology. 2021;8(4):60–70. (In Russ.). DOI: 10.21682/2311‑1267‑2021‑8‑4‑60‑70
9. Valiev T. T., Shervashidze M. A., Belysheva T. S. Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002. Oncohematology. 2022;17(3):137–159. (In Russ.). DOI: 10.17650/1818‑8346‑2022‑17‑3‑137‑159
10. Tjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999; 81 (4): 419–423. DOI: 10.1136/hrt.81.4.419
11. Lipshultz S. E., Giantris A. L., Lipsitz S. R. et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. Journal of Clinical Oncology. 2002; 20 (6): 1677–1682. PMID: 11925514.
12. Levitt G. A., Dorup I., Sørensen K., Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? British Journal of Haematology. 2004;124 (4): 463–468. DOI: 10.1111/j.1365-2141.2003.04992.x
13. Tjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999;81 (4): 419–423. DOI: 10.1136/hrt.81.4.419
14. Shah C. P., Moreb J. S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Therapeutic Advances in Cardiovascular Disease. 2019; 13: 175394471984343. DOI: 10.1177/1753944719843435
15. Pui CH, Cheng C, Leung W. et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349: 640–649. DOI: 10.1056/NEJMoa035091
16. Neglia JP, Meadows AT, Robison LL. et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 325: 1330–1336. DOI: 10.1056/NEJM199111073251902
17. Sklar CA, Mertens AC, Mitby P. et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87: 3136–3141. DOI: 10.1210/jcem.87.7.8606
18. Marie-Cécile Le Deley et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique. JCO 21: 1074–1081 (2003). DOI: 10.1200/JCO.2003.04.100
19. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R. Nordic Society for Paediatric Haematology and Oncology. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL‑92 study. Blood. 2009 Jun 11; 113 (24): 6077–84. DOI: 10.1182/blood‑2008‑11‑187880
20. Makhacheva F. A., Valiev T. T. Clinical features of secondary acute myeloid leukemia in children. Oncohematology. 2020; 15 (4): 12–17. (In Russ.). https://doi.org/10.17650/1818‑8346‑2020‑15‑4‑12‑17
21. Valiev T. T., Pavlova T. Yu., Kovrigina A. M., Serebryakova I. N. Acute myeloid leukemia as second tumor in a patient with Burkitt’s lymphoma: literature review and a case report. Clinical Oncohematology. Basic Research and Clinical Practice. 2021; 14 (2): 167–72. (In Russ.). DOI: 10.21320/2500‑2139‑2021‑14‑2‑167‑172
22. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006 Sep; 91 (9): 3494–8. DOI: 10.1210/jc.2006-0656
23. Fujii M, Ichikawa M, Iwatate K, Bakhit M, Yamada M, Kuromi Y, Sato T, Sakuma J, Sato H, Kikuta A, Suzuki Y, Saito K. Secondary brain tumors after cranial radiation therapy: A single-institution study. Rep Pract Oncol Radiother. 2020 Mar-Apr; 25 (2): 245–249. DOI: 10.1016/j.rpor.2020.01.009.
24. Korkina Yu.S., Valiev T. T. L-asparaginase: New about Well-Known Drug. Pediatric pharmacology. 2021; 18 (3): 227–232. (In Russ.). https://doi.org/10.15690/pf.v18i3.2282
25. Journy NMY, Zrafi WS, Bolle S, Fresneau B, Alapetite C, Allodji RS, Berchery D, Haddy N, Kobayashi I, Labbé M, Pacquement H, Pluchart C, Schwartz B, Souchard V, Thomas-Teinturier C, Veres C, Vu-Bezin G, Diallo I, de Vathaire F. Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2021 Jan; 30 (1): 133–141. DOI: 10.1158/1055-9965
26. Lee CY, Chen YW, Lee YY, Chang FC, Chen HH, Lin SC, Ho DM, Huang MC, Yen SH, Wong TT, Liang ML. Irradiation-Induced Secondary Tumors following Pediatric Central Nervous System Tumors: Experiences of a Single Institute in Taiwan (1975–2013). Int J Radiat Oncol Biol Phys. 2018 Aug 1; 101 (5): 1243–1252. DOI: 10.1016/j.ijrobp.2018.04.032
27. Le Deley M. C., Leblanc T., Shamsaldin A., Raquin M. A., Lacour B., Sommelet D., Chompret A., Cayuela J. M., Bayle C., Bernheim A., De Vathaire F., Vassal G., Hill C. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d’Oncologie Pédiatrique. Journal of Clinical Oncology. 2003; 21 (6): 1074–1081. https://doi.org/10.1200/JCO.2003.04.100
28. Mariël L. te Winkel, Rob Pieters, Wim C. J. Hop, Hester A. de Groot-Kruseman, Maarten H. Lequin, Inge M. van der Sluis, Jos P. M. Bökkerink, Jan A. Leeuw, Marrie C. A. Bruin, R. Maarten Egeler, Anjo J. P. Veerman, Marry M. van den Heuvel-Eibrink; A Prospective Study on Incidence, Risk Factors and Long-Term Outcome of Osteonecrosis in 694 Patients with Pediatric Acute Lymphoblastic Leukemia,. Blood. 2011; 118 (21): 3578. DOI: https://doi.org/10.1182/blood.V118.21.3578.3578
29. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000 Sep 15; 18 (18): 3262–72. DOI: 10.1200/JCO.2000.18.18.3262
30. Vlasova O. A., Zhidkova E. M., Lylova E. S. et al. Selective glucocorticoid receptor agonists as an alternative to glucocorticoids in the treatment of acute lymphoblastic leukemia: clinical response to glucocorticoids compared with molecular effects in vitro. Onikogematologiya – Oncohematology 2025; 20 (2): 80–6. (In Russ.). DOI: https://doi.org/10.17650/1818‑8346‑2025‑20‑2‑80‑86
31. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun; 129 (6): 734–45. DOI: 10.1111/j.1365–2141.2005.05509
32. Georg Mann, Franco Locatelli, Giovanni Cazzaniga, Felix Niggli, Maurizio Aricò, Claus R. Bartram, Andishe Attarbaschi, Daniela Silvestri, Rita Beier, Giuseppe Basso, Richard Ratei, Andreas E. Kulozik, Luca Lo Nigro, Bernhard Kremens, Jeanette Greiner, Rosanna Parasole, Jochen Harbott, Roberta Caruso, Arend von Stackelberg, Elena Barisone, Claudia Rössig, Valentino Conter, Martin Schrappe. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127 (17): 2101–2112. DOI: https://doi.org/10.1182/blood‑2015‑09‑670729
33. Marina Kunstreich, Sebastian Kummer, Hans-Juergen Laws, Arndt Borkhardt, Michaela Kuhlen. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016; 101 (11): 1295–1305. https://doi.org/10.3324/haematol.2016.147595
34. te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008; 93 (10): 1570–1574.
35. Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr. 2003; 215 (6): 327–331.
36. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11): 1096–1106.
37. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol. 2001; 28 (12): 993–996.
38. Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014; 89 (6): 817–834.
39. Stuart FA, Segal TY, Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child. 2005; 90 (5): 500–506.
40. Anastasopoulou S, Swann G, Andres-Jensen L, Attarbaschi A, Barzilai-Birenboim S, Erdelyi DJ, Escherich G, Hamadeh L, Harila A, Lopez-Lopez E, McGowan S, Möricke A, Putti C, Sagi JC, Schmiegelow K, Ullrich NJ, van der Sluis IM, Wahid QU, Winick N, Sramkova L, Zalcberg Y, Zapotocka E, Bhojwani D, Halsey C; Ponte Di Legno Neurotoxicity Working Group. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study. Br J Haematol. 2024 Oct; 205 (4): 1450–1459. DOI: 10.1111/bjh.19610
41. Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00–01. Pediatr Blood Cancer. 2011 Sep; 57 (3): 492–8. DOI: 10.1002/pbc.23060
42. Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys. 1992; 22: 13–16. DOI: 10.1016/0360–3016(92)90976-o
43. Muriel AC, Burgers DE, Treyball AN, Vrooman LM, Adolf E, Samsel C. Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021; 68 (5): e28847
44. Sklar CA, Mertens AC, Walter A. et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000; 35: 91–95. DOI: 10.1002/1096-911x(200008)35:2<91:: aid-mpo1>3.0.co
45. Oeffinger KC, Mertens AC, Sklar CA, et al. Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003; 21: 1359–1365. DOI: 10.1200/JCO.2003.06.131
46. Sklar CA, Robison LL, Nesbit ME, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990; 8: 1981–1987. DOI: 10.1200/JCO.1990.8.12.1981
47. Kravchenko N. E., Suetina O. A., Sachuk O. V., Valiev T. T. Mental health disorders in oncohematological diseases in children and adolescents. Medical Alphabet. 2023; (17): 26–31. (In Russ.).
48. Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol. 1993; 21: 333–339. DOI: 10.1002/mpo.2950210505
49. Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004; 13: 689–690. DOI: 10.1002/pon.784
50. Kanellopoulos A., Andersson S., Zeller B., Tamnes C. K., Fjell A. M., Walhovd K. B., Westlye L. T., Fosså S. D. Ruud E. Neurocognitive Outcome in Very Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia After Treatment with Chemotherapy Only. Pediatr Blood Cancer 2016; 63: 133–138. https://doi.org/10.1002/pbc.25690
51. Klyut A. S., Kharbediya V. Kh., Abrahamyan D. G. et al. Analysis of functional disorders in oncohematological diseases survivours. MD-Onco 2024; 4 (4): 129–35. (In Russ.). DOI: https:// doi.org/10.17650/2782‑3202‑2024‑4‑4‑129‑135
52. Pavlova M. G., Tselovalnikova T. Yu., Yudina A. E., Golounina O. O., Zilov A. V., Mazerkina N. A., Zheludkova O. G., Fadeev V. V. Growth hormone deficiency in childhood brain tumors and acute lymphoblastic leukemia survivors. Obesity and metabolism. 2021; 18 (4): 484–495. (In Russ.). DOI: https://doi.org/10.14341/omet12786
Review
For citations:
Sittigullina A.R., Kharbediya V.Kh., Belysheva T.S. Long-term effects of antitumor treatment of acute lymphoblastic leukemia. Medical alphabet. 2025;(26):41‑48. (In Russ.) https://doi.org/10.33667/2078-5631-2025-26-41-48
Views:
15
Email this article 